JP7575400B2 - バイオマーカーに基づく遠隔患者管理の処方 - Google Patents

バイオマーカーに基づく遠隔患者管理の処方 Download PDF

Info

Publication number
JP7575400B2
JP7575400B2 JP2021556866A JP2021556866A JP7575400B2 JP 7575400 B2 JP7575400 B2 JP 7575400B2 JP 2021556866 A JP2021556866 A JP 2021556866A JP 2021556866 A JP2021556866 A JP 2021556866A JP 7575400 B2 JP7575400 B2 JP 7575400B2
Authority
JP
Japan
Prior art keywords
level
biomarker
patients
patient
proadm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556866A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020201078A5 (https=
JP2022526507A5 (https=
JP2022526507A (ja
Inventor
トビアス スチューベ
ヤン ウィーマー
ヤン クンデ
シュテファン ゲーリヒ
フリードリヒ ケーラー
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19166382.2A external-priority patent/EP3715851A1/en
Application filed by ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022526507A publication Critical patent/JP2022526507A/ja
Publication of JPWO2020201078A5 publication Critical patent/JPWO2020201078A5/ja
Publication of JP2022526507A5 publication Critical patent/JP2022526507A5/ja
Priority to JP2024181851A priority Critical patent/JP2025015545A/ja
Application granted granted Critical
Publication of JP7575400B2 publication Critical patent/JP7575400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
JP2021556866A 2019-03-29 2020-03-27 バイオマーカーに基づく遠隔患者管理の処方 Active JP7575400B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024181851A JP2025015545A (ja) 2019-03-29 2024-10-17 バイオマーカーに基づく遠隔患者管理の処方

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19166425.9 2019-03-29
EP19166382.2A EP3715851A1 (en) 2019-03-29 2019-03-29 Prescription of remote patient management based on biomarkers
EP19166382.2 2019-03-29
EP19166425 2019-03-29
EP19175720.2 2019-05-21
EP19175720 2019-05-21
PCT/EP2020/058700 WO2020201078A1 (en) 2019-03-29 2020-03-27 Prescription of remote patient management based on biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024181851A Division JP2025015545A (ja) 2019-03-29 2024-10-17 バイオマーカーに基づく遠隔患者管理の処方

Publications (4)

Publication Number Publication Date
JP2022526507A JP2022526507A (ja) 2022-05-25
JPWO2020201078A5 JPWO2020201078A5 (https=) 2023-04-05
JP2022526507A5 JP2022526507A5 (https=) 2023-04-05
JP7575400B2 true JP7575400B2 (ja) 2024-10-29

Family

ID=69941398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556866A Active JP7575400B2 (ja) 2019-03-29 2020-03-27 バイオマーカーに基づく遠隔患者管理の処方
JP2024181851A Pending JP2025015545A (ja) 2019-03-29 2024-10-17 バイオマーカーに基づく遠隔患者管理の処方

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024181851A Pending JP2025015545A (ja) 2019-03-29 2024-10-17 バイオマーカーに基づく遠隔患者管理の処方

Country Status (8)

Country Link
US (2) US12442825B2 (https=)
EP (1) EP3948301A1 (https=)
JP (2) JP7575400B2 (https=)
CN (1) CN113348368A (https=)
AU (1) AU2020253042B2 (https=)
BR (1) BR112021019479A2 (https=)
CA (3) CA3281050A1 (https=)
WO (1) WO2020201078A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11783944B2 (en) * 2019-09-09 2023-10-10 Neal F. Krouse System for live monitoring of vitals for patients and physicians
WO2022101937A1 (en) * 2020-11-12 2022-05-19 Shah Komal An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure
WO2022164724A1 (en) * 2021-01-27 2022-08-04 Verantos, Inc. High validity real-world evidence study with deep phenotyping
WO2022245405A1 (en) 2021-05-17 2022-11-24 Verantos, Inc. System and method for term disambiguation
US20240120105A1 (en) * 2022-10-09 2024-04-11 Morteza Naghavi Predicting adverse health risk based on ct scan images and ai-enabled cardiovascular structure volumetry
WO2025097159A1 (en) * 2023-11-05 2025-05-08 3Ive Labs, Llc Urinary oxygen and uses thereof in adaptive therapies for kidney function

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US4121573A (en) 1973-10-04 1978-10-24 Goebel Fixture Co. Wireless cardiac monitoring system and electrode-transmitter therefor
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4827943A (en) 1986-09-23 1989-05-09 Advanced Medical Technologies, Inc. Portable, multi-channel, physiological data monitoring system
US4784162A (en) 1986-09-23 1988-11-15 Advanced Medical Technologies Portable, multi-channel, physiological data monitoring system
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
US5511553A (en) 1989-02-15 1996-04-30 Segalowitz; Jacob Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously
US5307818A (en) 1989-02-15 1994-05-03 Jacob Segalowitz Wireless electrocardiographic and monitoring system and wireless electrode assemblies for same
US4981141A (en) 1989-02-15 1991-01-01 Jacob Segalowitz Wireless electrocardiographic monitoring system
US5168874A (en) 1989-02-15 1992-12-08 Jacob Segalowitz Wireless electrode structure for use in patient monitoring system
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
US5353793A (en) 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5214939A (en) 1991-11-25 1993-06-01 Carrier Corporation Variable area refrigerant expansion device having a flexible orifice
ES2155068T3 (es) 1992-04-03 2001-05-01 Micromedical Ind Ltd Sistema de supervision fisiologica.
US5522396A (en) 1992-05-12 1996-06-04 Cardiac Telecom Corporation Method and system for monitoring the heart of a patient
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US5544661A (en) 1994-01-13 1996-08-13 Charles L. Davis Real time ambulatory patient monitor
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007022367A1 (de) 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2107377A1 (en) * 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
CN105044349B (zh) * 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CN108931658A (zh) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 用于诊断心力衰竭合并症及预后评估的血清标记物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOEHLER FRIEDRICH et al.，Telemedicine in heart failure: Pre-specified and exploratory subgroup analyses from the TIM-HF trial，Int. J. cardiol.，2012年，Vol.161,No.3，P.143-150

Also Published As

Publication number Publication date
CA3281050A1 (en) 2026-03-02
CN113348368A (zh) 2021-09-03
US20220260589A1 (en) 2022-08-18
CA3281038A1 (en) 2026-03-02
AU2020253042A1 (en) 2021-06-17
BR112021019479A2 (pt) 2021-11-30
CA3124744A1 (en) 2020-10-08
AU2020253042B2 (en) 2025-10-02
US20250369987A1 (en) 2025-12-04
JP2025015545A (ja) 2025-01-30
WO2020201078A1 (en) 2020-10-08
US12442825B2 (en) 2025-10-14
JP2022526507A (ja) 2022-05-25
EP3948301A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
JP7575400B2 (ja) バイオマーカーに基づく遠隔患者管理の処方
Bachmann et al. Unexpectedly low natriuretic peptide levels in patients with heart failure
JP6902083B2 (ja) マルチマーカーリスク層別化
JP6788050B2 (ja) 主要有害心イベントのリスクを予測する方法
Frank Peacock et al. Short‐term mortality risk in emergency department acute heart failure
Potocki et al. Comparison of midregional pro‐atrial natriuretic peptide with N‐terminal pro‐B‐type natriuretic peptide in the diagnosis of heart failure
EP2386860A2 (en) Predicting mortality and detecting severe disease
Patton et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study
Savic‐Radojevic et al. The role of serum VCAM‐1 and TNF‐α as predictors of mortality and morbidity in patients with chronic heart failure
Iqbal et al. Novel biomarkers for heart failure
van Peet et al. Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study
Vallée Association between serum uric acid and arterial stiffness in a large‐aged 40–70 years old population
Meune et al. Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin
EP3715851A1 (en) Prescription of remote patient management based on biomarkers
Tawfeeq et al. The impact of COVID-19 on BNP, NT-proBNP and ANP in heart failure
Nakagawa et al. Right ventricular dimension for heart failure with preserved ejection fraction involving right ventricular-vascular uncoupling
RU2822013C2 (ru) Назначение дистанционного ведения пациентов на основе биомаркеров
Busch et al. Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes
Wang et al. Development of a predictive risk stratification tool to identify population over 45 at risk of new-onset stroke in seven years
Maisel Clinical use of natriuretic peptides for the diagnosis and management of heart failure
Gustafsson Risk Stratification in Advanced Heart Failure
Bethell et al. The relationship between BNP and risk assessment in cardiac rehabilitation patients
Kuroda Very Early Diuretic Response After Admission for Acute Heart Failure Kuroda, Shunsuke; Damman, Kevin; Ter Maaten, Jozine M.; Voors, Adriaan A.; Okumura, Takahiro; Kida, Keisuke; Oishi, Shogo; Akiyama, Eiichi; Suzuki, Satoshi; Yamamoto, Masayoshi

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241017

R150 Certificate of patent or registration of utility model

Ref document number: 7575400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150